Singapore Qritive Collaborates with Roche to Enhance AI Cancer Diagnostics

Qritive and Roche Collaborate to Advance Cancer Diagnostics

Singapore Qritive, a premier digital pathology and AI firm, proudly announces its partnership with Roche, a leading global diagnostics and life sciences company. This collaboration marks a pivotal step in enhancing cancer diagnostics and streamlining the adoption of AI tools by pathologists.

AI Integration for Optimized Patient Outcomes

By integrating Qritive's QAI Prostate Grade algorithm into the Roche NAVIFY Digital Pathology platform, pathologists can effectively utilize AI to conduct more precise and efficient cancer diagnoses. This results in a significant reduction in time to treatment, ultimately leading to better patient outcomes.

Enhanced Diagnostic Tools for Multiple Cancers

• Clinically validated AI modules are tailored for colon, prostate, breast, and gastric cancers.
• These advanced tools analyze whole slide images to accurately identify and grade tumors.
• Reports indicate improved pathology reporting time by up to 10-fold.
• The modules also significantly reduce the risk of misdiagnosis.

As Bruno Occhipinti, CEO of Qritive, emphasized, "We are genuinely excited to see how the integration of our AI-powered solutions within the highly performing Roche NAVIFY Digital Pathology platform will augment pathologists' performance, enabling affordable and accurate diagnostics at scale." This collaboration underscores Qritive's commitment to empowering pathologists worldwide with state-of-the-art AI solutions.

Future of Cancer Diagnostics

By expanding the reach of its innovative AI-based pathology solutions, Qritive continues to play a crucial role in the future of cancer diagnostics, positively influencing the healthcare system and improving health outcomes globally.